Specifically, in experiments in which EML4-ALK–positive NSCLC cells were treated with ALK inhibitors, the phosphorylation of ALK itself, PTPN11, FAF2, and SHC1 was strongly inhibited by gilteritinib, whereas the phosphorylation of other sites was inhibited to a lesser degree (Fig S5). Here, FAF2 is linked to non-small cell lung carcinoma.